The kit utilizes multiplex fluorescent PCR technology for the qualitative detection of three prevalent KIAA1549-BRAF gene fusions in RNA extracted from FFPE glioma tissue specimens.


This kit supports molecular subtyping and prognostic risk assessment in pediatric low-grade glioma patients. It helps clinicians screen patients eligible for BRAF-targeted therapy and informs individualized targeted treatment planning.
The intended population is glioma patients, particularly those with pediatric low-grade gliomas.
1.Nucleic Acid Extraction
2.Sample Loading
3.Instrument Run
4.Report Generation
闽公网安备35021202000745